← Leaderboards
Hedia Maamar
Talis Biomedical Corporation
$1,178,848
Attributed
$2,357,695
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–19$2M$1.5M$1M$500K$0
'18
'19
Funding mix
By agency
NIH$2,357,695 · 1
By mechanism
R01$2,357,695 · 1
Top collaborators
- Martin Goldberg2 shared
Most similar at Talis Biomedical Corporation
Same institution · by research overlap
- Martin Goldberg$1,178,848
- Betty B Wu$2,219,076
- Kyle Andrew Tipton$1,109,538
Others in their field
Other Emerging Leaders on “Antibiotic Resistance”
- Urs Ochsner · Crestone, Inc.$36,950,837
- Ryan Cirz · Revagenix, Inc.$35,410,554
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$25,064,821
- Bruce Blough · Research Triangle Institute$19,880,022
- Thomas Dick · Rbhs-New Jersey Medical School$15,241,285
- Terry Roemer · Prokaryotics, Inc.$13,917,276
Research focus
Antibiotic ResistanceAmericanAntibioticsAntibiotic SusceptibilityAntibiotic-Resistant OrganismAntimicrobialAntimicrobial ResistanceAntimicrobial SusceptibilityAreaBacterial Antibiotic ResistanceAntibiotic TherapyBaseBioinformaticsBloodBlood SpecimenCaliforniaCandida AlbicansCenters For Disease Control And Prevention (U.S.)ChemistryChicagoClinical DevelopmentCommunicable DiseasesBacterial ResistanceCost
Grant awards (2)
Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood.$1,106,115
R01 · FY2019 · AI
Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood.$1,251,580
R01 · FY2018 · AI